The MedicQuant reader with a test cartridge loaded, next to a cartridge pouch and sample vials

Rapid answers for life-saving treatment

A quantitative DOAC level from whole blood in 10 minutes, measured at the bedside, while the stroke team decides.

Follow one test

Peer reviewed in ACS Sensors, July 2026. Read the paper

From one drop of blood to a number the neurologist can act on

Scroll through a single measurement. The cartridge on the left does what the text on the right describes.

  1. A drop of whole blood

    No centrifuge and no plasma preparation. The sample goes straight from the patient into a single disposable cartridge.

  2. Red cells stay behind

    A blood separation filter holds back the red cells. Plasma moves on along a glass fibre strip by capillary action alone.

  3. The plasma dissolves two dried reagents

    An antibody-DNA conjugate and an analyte-DNA strand. If the anticoagulant is in the sample, it competes for the antibody and changes how the DNA labels sit together.

  4. The reader asks with light

    It excites the Cy3 dye and measures emission from Cy3 and Cy5. With no drug present, energy transfers (FRET). With drug present, it does not. The ratio is the measurement.

  5. A level, not a guess

    The screen shows a quantitative DOAC concentration, with accuracy comparable to laboratory standards. The thrombolysis decision no longer waits for the central lab.

Intermediate timings are illustrative. Total time to result, as stated by MedicQuant: 10 minutes.

In acute stroke, the anticoagulant level is the last unknown

Patients on direct oral anticoagulants arrive with a question nobody can answer at the bedside today. MedicQuant was built around that wait.

The wait

Before thrombolysis, clinicians need to know how much DOAC is still in the blood.

"DOAC levels are the only thing we wait for currently before thrombolysis."Neurologist, interviewed by MedicQuant

The answer

A quantitative level, comparable to laboratory standards, on the reader next to the patient.

Central lab routetransport, spin, queue
MedicQuant at the bedside10 min

The user

Designed for emergency staff, not lab specialists. Users at relevant sites rated the system easy or very easy.

How easy was the system to use?
Very hardHardNeutralEasyVery easy

A platform for small-molecule drugs in whole blood

The cartridge and reader are built on patent-pending DNA nanotechnology. Anticoagulants come first. The same principle has been shown for other drug classes.

First product

Anticoagulants

  • Direct oral anticoagulants (DOACs)
  • Emergency and stroke care
  • Point of care, whole blood
Proof of concept

Antibiotics

  • Drug level at the bedside
  • Same cartridge principle
Proof of concept

Anticancer drugs

  • Small-molecule therapies
  • Same reader
Proof of concept

Antirheumatic drugs

  • Small-molecule therapies
  • Precision dosing

Evidence and recent news

ACS Sensors · 2 July 2026

A Point-of-Care System for the Quantification of Small-Molecule Drugs in Blood

Read the publication
Startup of the Year 2026 nominee badge, INCUBA
October 2026

Nominated for Startup of the Year 2026 at the INCUBA Awards

MedicQuant CTO at the DSG26 stroke congress in Berlin
September 2026

Presenting to stroke specialists at DSG26 in Berlin

Line Debois Frejlev Nielsen, CEO and co-founder

Scientists from Aarhus, building for the emergency room

Led by CEO Line Debois Frejlev Nielsen and CTO Malthe Hansen-Bruhn, with hardware, quality and regulatory in house.

Meet the team

Raising our second equity round

Selected for the EIC Accelerator in 2026, with public and private investors behind us. We are looking for new investors to join existing ones on the way to market.

€2.5MEIC Accelerator grant, 2026
10 minwhole blood to result
Talk to the CEO
EIFO Volver VC Innovation Fund Denmark Delphinus MIF BI Aarhus University Funded by the European Union EIT